Phenytoin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Phenytoin: From Epilepsy to Trigeminal Neuralgia
One-Sentence Summary
Phenytoin is a long-established sodium-channel-blocking anticonvulsant, used for decades in the management of epilepsy and seizure disorders. Across the ten candidate indications generated by the TxGNN model for this drug, Trigeminal Neuralgia is the only one supported by genuine clinical evidence — 1 completed prospective clinical trial and 9 relevant publications, including a European clinical guideline and a 144-patient retrospective study of intravenous phenytoin for acute pain crises.
Note on candidate selection: TxGNN’s single highest-scoring prediction for phenytoin was “trigeminal nerve neoplasm” (score 99.99%). On review, this was assessed by the evidence pipeline itself as a disease-entity mismatch — the associated literature concerns trigeminal neuralgia and unrelated conditions (Sturge-Weber syndrome, dermatology case series), not tumour biology, and phenytoin has no known antineoplastic activity. This report instead evaluates the TxGNN candidate with the strongest supporting evidence base, trigeminal neuralgia.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy / seizure disorders (long-established use; not captured in structured ARTG licence data for this drug — see Australia Market Information) |
| Predicted New Indication | Trigeminal Neuralgia |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L2 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for phenytoin is not available in this evidence pack. Based on known pharmacology, phenytoin is a voltage-gated sodium channel blocker — the same mechanistic class as carbamazepine and oxcarbazepine, the current first-line drugs for trigeminal neuralgia. This shared mechanism is the basis for the TxGNN prediction: by stabilising the inactivated state of neuronal sodium channels, phenytoin can dampen the paroxysmal, high-frequency neuronal discharges thought to underlie trigeminal neuralgia’s characteristic stabbing facial pain, just as it does for epileptic discharges in its original indication.
Epilepsy and trigeminal neuralgia are pharmacologically linked conditions: several anticonvulsants (carbamazepine, oxcarbazepine, lamotrigine) are already standard therapy for both. Phenytoin’s use in trigeminal neuralgia is not new — it has long been used as an alternative or adjunct, particularly in an intravenous formulation for acute pain exacerbations when oral first-line agents cannot be tolerated or absorbed (e.g., during dehydration or anorexia from severe pain crises).
Unlike most of the other TxGNN candidates for this drug (e.g., startle epilepsy, audiogenic seizures, eating seizures), which are supported only by animal models or unrelated literature, trigeminal neuralgia has a completed prospective human trial directly testing IV phenytoin in this indication, plus a substantial retrospective clinical experience — making it the most credible repurposing signal in this candidate set.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT03712254 | N/A | Completed | 15 | Prospective systematic study of IV phenytoin for acute exacerbations of trigeminal neuralgia in patients unable to tolerate oral first-line therapy (carbamazepine/oxcarbazepine) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30860637 | 2019 | Guideline | European Journal of Neurology | European Academy of Neurology guideline on diagnosis and management of trigeminal neuralgia |
| 35469475 | 2022 | Clinical Study | Cephalalgia | Retrospective analysis of 144 cases using IV lacosamide and IV phenytoin for acute trigeminal neuralgia exacerbations |
| 32981076 | 2020 | Case Series | Headache | Retrospective cohort on IV phenytoin as acute rescue treatment for trigeminal neuralgia crisis |
| 28761370 | 2017 | Review/Comparative | Journal of Pain Research | Comparative analysis of phenytoin and carbamazepine in trigeminal neuralgia — marketing-based vs evidence-based treatment choices |
| 31908187 | 2020 | Review | Molecular Pain | Overview of trigeminal neuralgia pathophysiology and pharmacological treatment options, including sodium channel blockers |
| 29114270 | 2017 | Review | Asian Journal of Neurosurgery | General review of trigeminal neuralgia diagnosis and management |
| 19445753 | 2009 | Review | BMJ Clinical Evidence | Evidence review of trigeminal neuralgia treatments |
| 15062534 | 2004 | Review | Neurologic Clinics | Review of trigeminal and glossopharyngeal neuralgia, noting antiepileptic drugs as most effective agents |
| 38421578 | 2024 | Review | CNS Drugs | Review of neuropathic pain management in multiple sclerosis, including trigeminal neuralgia |
Australia Market Information
Phenytoin currently has no ARTG entries and is not marketed in Australia according to available regulatory data.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One completed prospective trial and a substantial retrospective case series (144 patients) support IV phenytoin as a rescue option for acute trigeminal neuralgia exacerbations, with a mechanistically plausible link to its established antiepileptic action. However, evidence is limited to small/retrospective studies rather than a confirmatory RCT, and phenytoin is not currently registered in Australia.
To proceed, the following is needed:
- Product Information (PI) safety data — key warnings, contraindications, and drug interactions (currently a data gap)
- Formal mechanism of action documentation from DrugBank or equivalent
- Confirmation of ARTG registration pathway, since the drug is not currently marketed in Australia
- A prospective randomised comparison against standard first-line therapy (carbamazepine/oxcarbazepine) to confirm efficacy beyond retrospective/observational evidence
- Route-specific safety review for IV administration (relevant given the trial and case-series evidence used IV formulation)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.